Pricing Log in Create free account
Monday 2 November 2026 Export TWST’s income statement to Excel — free account

Twist Bioscience Corporation

TWST Healthcare Biotechnology

Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.

Revenue
+23.2%
EPS
−264.7%
Free cash flow
−7.23%
Total debt
0.00%

Quarter to June 2026, against a year earlier

129.86 22.92 −15.00%
Market cap
$10.1B
P/E
0.0×
Fwd P/E
−91.4×
Dividend yield
—
F-score
4/9
Altman Z
3.44
Beneish M
−2.30
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Twist Bioscience Corporation (TWST) SEC filings, changes and red flags

Red flags

  • Material weakness

    Twist Bioscience Corporation’s 10-K reports a material weakness in internal control over financial reporting

    changes related to the remediation of the previously identified material weakness noted above

    10-K filed · The filing · sec.gov

Filings

Form Period Filed What it reports Flags
8-K Aug 19, 2026 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 18, 2026 7.01 Regulation FD disclosure
8-K Aug 4, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 14 added · 5 removed · 28 modified
P2I1A: no material changes, the filing says
8-K Aug 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 11, 2026 3.02 Unregistered sales of equity securities; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Feb 5, 2026 5.07 Submission of matters to a vote of security holders
10-Q Dec 31, 2025
8-K Feb 2, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Sep 30, 2025 1: 6 added · 31 removed · 50 modified
1A: 24 added · 18 removed · 94 modified
7: 17 added · 36 removed · 36 modified
8-K Nov 14, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 4, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K May 2, 2025 1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Dec 31, 2024
8-K Feb 3, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Sep 30, 2024 Material weakness
8-K Nov 18, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Aug 2, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 2, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 2, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 17, 2023 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.